medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (2)

Alopecia areata universalis treated with oral pulse of dexamethasone. A case report

Vera RV, Arrazola MKS

Language: Spanish
References: 15
Page: 143-147
PDF size: 428.86 Kb.


ABSTRACT

Alopecia areata is an autoimmune disease that results in nonscarring hair loss, clinically characterized by small patches of baldness isolated or confluent, it can later progress to total loss of scalp hair (alopecia totalis) or total loss of all hair body (alopecia universalis) which can affect beard, underarm hair, pubic or any hair-bearing sites.
We report a 22-year-old female patient who consulted with alopecic areas on the scalp, eyelashes, armpits, pubis, and upper and lower limbs. According to the clinical, trichoscopic and interrogation characteristics, alopecia areata universalis was diagnosed and treatment was started with pulses of oral dexamethasone, with a total regrowth of the alopecic areas.


REFERENCES

  1. Simakou T, Butcher JP, Reid S y Henriquez FL, Alopecia areata: a multifactorialautoimmune condition, J Autoimmun 2019; 98:74-85.

  2. Strazzulla LC, Wang EHC, Ávila L, Lo Sicco, Brinster N, Christiano AMet al., Alopecia areata. Disease characteristics, clinical evaluation andnew perspectives on pathogenesis, J Am Acad Dermatol 2017; 78:1-12.

  3. Lee S y Lee WS, Management of alopecia areata: updates and algorithmicapproach, J Dermatol 2017; 44:1199-211.

  4. Pratt CH, King LE, Messenger AG, Christiano AM y Sundberg JP, Alopeciaareata, Nat Rev Dis Primers 2017; 03:1-17.

  5. Burroway B, Griggs J y Tosti A, Alopecia totalis and universalis longtermoutcomes: a review, J Eur Acad Dermatol Venereol 2020; 34:709-15.

  6. Was´kiel A, Rakowska A, Sikora M, Olszewska M y Rudnicka L, Trichoscopyof alopecia areata: an update, J Dermatol 2018; 45:692-700.

  7. MacDonald HSP, Wood ML, Hutchinson PE, Sladden M y MessengerAG, Guidelines for the management of alopecia, Br J Dermatol 2003;149:692-9.

  8. Rossi A, Muscianese M, Piaraccini B, Starace M, Carlesimo M, ManderlV et al., Guidelines in diagnosis and treatment of alopecia areata, G ItalDermatol Venereol 2019; 154:609-23.

  9. Kassira S, Korta DZ, Chapman LW y Dann F, Review of treatment foralopecia totalis and alopecia universalis, Int J Dermatol 2017; 56: 801-10.

  10. Strazzulla LC, Wang EHC, Ávila L, Lo Sicco, Brinster N, Christiano AMet al., Alopecia areata. An appraisal of new treatment approaches andoverview of current therapies, J Am Acad Dermatol 2018; 78:15-24.

  11. Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G et al.,An open-label pilot study to evaluate the efficacy of tofacitinib inmoderate to severe patch-type alopecia areata, totalis, and universalis,J Invest Dermatol 2018; 138:1539-45.

  12. Liu LY, Craiglow BG, Dai F y King BA, Tofacitinib for the treatment ofsevere alopecia areata and variants: a study of 90 patients, J Am AcadDermatol 2017; 76:22-8.

  13. Galán-Gutiérrez M, Rodríguez-Bujaldón A y Moreno-Giménez C, Actualizaciónterapéutica en alopecia areata, Actas Dermosifiliogr 2009;100:266-76.

  14. Vañó-Galván S, Hermosa-Gelbard A, Sánchez-Neila N, Miguel-GómezL, Saceda-Corralo D, Rodrigues B et al., Pulse corticosteroid therapywith oral dexamethasone for the treatment of adult alopecia totalisand universalis, J Am Acad Dermatol 2016; 74:1005-7.

  15. Sharma VK y Gupta S, Twice weekly 5 mg dexamethasone oral pulsein the treatment of extensive alopecia areata, J Dermatol 1999; 26:562-5.




2020     |     www.medigraphic.com